Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Apoptosis-prone phenotype of human colon carcinoma cells with a high level amplification of the c-myc gene

Abstract

Although apoptosis can be induced by the enforced expression of exogenously introduced c-myc genes, it is not clear whether overexpression resulting from the amplification of the resident c-myc gene in tumor cells is sufficient to induce apoptosis. We have investigated the relationship between c-myc gene amplification and the propensity of tumor cells to undergo apoptosis, using the SW613-12A1 and SW613-B3 cell lines, which are representatives, respectively, of tumorigenic and non-tumorigenic clones isolated from the SW613-S human colon carcinoma cell line. Tumorigenic clones are characterized by a high level of amplification and expression of the c-myc gene, whereas cells of non-tumorigenic clones have a small number of copies and a lower level of expression of this gene. Analysis of c-myc mRNA level in cells cultured under low serum conditions indicated that the expression of the gene is tightly regulated by serum growth factors in non-tumorigenic B3 cells, whereas it is poorly regulated in tumorigenic 12A1 cells, the level of mRNAs remaining relatively high in serum-starved 12A1 cells. Under these conditions, 12A1 cells showed clear evidence of apoptosis, whereas B3 cells were completely refractory to the induction of apoptosis. Moreover, the study of cell lines derived from non-tumorigenic apoptosis-resistant clones following the introduction by transfection of exogenous c-myc gene copies showed that they have acquired an apoptosis-prone phenotype. Altogether, our results strongly suggest that deregulated c-myc expression due to high-level amplification confers an apoptosis-prone phenotype to tumor cells. The possible consequences of these observations for cancer therapy are discussed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

Abbreviations

BCIP:

5-bromochloro-3-indolyl phosphate

DGGE:

denaturing gradient gel electrophoresis

DMEM:

Dulbecco's modified Eagle medium

NBT:

p-nitrotetrazolium blue

PARP:

poly(ADP-ribose) polymerase

PBS:

phosphate buffered saline

SDS – PAGE:

sodium dodecyl sulphate-polyacrylamide gel electrophoresis

References

  • Alarcon RM, Rupnow BA, Graeber TG, Knox SJ and Giaccia AJ. . 1996 Cancer Res. 56: 4315–4319.

  • Amati B and Land H. . 1994 Curr. Opin. Genet. Dev. 4: 102–108.

  • Askew DS, Ashmun RA, Simmons BC and Cleveland JL. . 1991 Oncogene 6: 1915–1922.

  • Augenlicht LH, Wadler S, Corner G, Richards C, Ryan L, Multani AS, Pathak S, Benson A, Haller D and Heerdt BG. . 1997 Cancer Res. 57: 1769–1775.

  • Barbu V and Dautry F. . 1989 Nucleic. Acids Res. 17: 7115.

  • Bishop JM. . 1995 Genes & Dev. 9: 1309–1315.

  • Bissonnette RP, Echeverri F, Mahboubi A and Green DR. . 1992 Nature 359: 552–554.

  • Bracey TS, Miller JC, Preece A and Paraskeva C. . 1995 Oncogene 10: 2391–2396.

  • Brison O. . 1993 Biochim. Biophys. Acta 1155: 25–41.

  • Chinnaiyan AM, Orth K, O'Rourke K, Duan H, Poirier GG and Dixit VM. . 1996 J. Biol. Chem. 271: 4573–4576.

  • Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P and Traganos F. . 1992 Cytometry 13: 795–808.

  • Dautry F, Weil D, Yu J and Dautry-Varsat A. . 1988 J. Biol. Chem. 263: 17615–17620.

  • Davis AC, Wims M, Spotts GD, Hann SR and Bradley A. . 1993 Genes & Dev. 7: 671–682.

  • Dong J, Naito M and Tsuruo T. . 1997 Oncogene 15: 639–647.

  • El-Deiry WS. . 1997 Curr. Opin. Oncol. 9: 79–87.

  • Endicott JA and Ling V. . 1989 Annu. Rev. Biochem. 38: 137–171.

  • Erisman MD, Rothberg PG, Diehl RE, Morse CC, Spandorfer JM and Astrin SM. . 1985 Mol. Cell. Biol. 5: 1969–1976.

  • Evan GI and Littlewood TD. . 1993 Curr. Opin. Genet. Dev. 3: 44–49.

  • Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ and Hancock DC. . 1992 Cell 69: 119–128.

  • Fanidi A, Harrington EA and Evan GI. . 1992 Nature 359: 554–556.

  • Fukasawa K, Wiener F, Vande Woude GF and Mai S. . 1997 Oncogene 15: 1295–1302.

  • Galdemard C, Brison O and Lavialle C. . 1995 Oncogene 10: 2331–2342.

  • Guano F, Bernardi R, Donzelli M, Prosperi E, Astaldi Ricotti G and Scovassi AI. . 1994 Cell Death Diff. 1: 101–107.

  • Hague A, Hicks DJ, Bracey TS and Paraskeva C. . 1997 Br. J. Cancer 75: 960–968.

  • Hague A, Manning AM, Hanlon KA, Huschtscha LI, Hart D and Paraskeva C. . 1993 Int. J. Cancer 55: 498–505.

  • Han J, Dionne CA, Kedersha NL and Goldmacher VS. . 1997 Cancer Res. 57: 176–182.

  • Harrington EA, Bennett MR, Fanidi A and Evan GI. . 1994a EMBO J. 13: 3286–3295.

  • Harrington EA, Fanidi A and Evan GI. . 1994b Curr. Opin. Genet. Dev. 4: 120–129.

  • Haupt Y, Rowan S and Oren M. . 1995 Oncogene 10: 1563–1571.

  • Hermeking H and Eick D. . 1994 Science 265: 2091–2093.

  • Hoffman B and Liebermann DA. . 1994 Oncogene 9: 1807–1812.

  • Hueber A-O, Zörnig M, Lyon D, Suda T, Nagata S and Evan GI. . 1997 Science 278: 1305–1309.

  • Kangas A, Nicholson DW and Hölttä E. . 1998 Oncogene 16: 387–398.

  • Lamarre D, Talbot B, de Murcia G, Laplante C, Leduc Y, Mazen A and Poirier GG. . 1988 Biochim. Biophys. Acta 950: 147–160.

  • Lamonerie T, Lavialle C, Haddada H and Brison O. . 1995 Int. J. Cancer 61: 587–592.

  • Lavialle C, Modjtahedi N, Cassingena R and Brison O. . 1988 Oncogene 3: 335–339.

  • Lavialle C, Modjtahedi N, Cassingena R and Brison O. . 1990 Oncogene 5: 245.

  • Lavialle C, Modjtahedi N, Lamonerie T, Frebourg T, Landin R-M, Fossar N, Lhomond G, Cassingena R and Brison O. . 1989 Anticancer Res. 9: 1265–1280.

  • Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG and Earnshaw WC. . 1994 Nature 371: 346–347.

  • Levine AJ. . 1993 Annu. Rev. Biochem. 62: 623–651.

  • Lowe SW, Schmitt EM, Smith SW, Osborne BA and Jacks T. . 1993 Nature 362: 847–849.

  • Marcu KB, Bossone SA and Patel AJ. . 1992 Annu. Rev. Biochem. 61: 809–860.

  • Marx J. . 1993 Science 259: 760–761.

  • Modjtahedi N, Haddada H, Lamonerie T, Lazar E, Lavialle C and Brison O. . 1992 Int. J. Cancer 52: 483–490.

  • Modjtahedi N, Lavialle C, Poupon M-F, Landin R-M, Cassingena R, Monier R and Brison O. . 1985 Cancer Res. 45: 4372–4379.

  • Negri C, Bernardi R, Donzelli M and Scovassi AI. . 1995 Biochimie 77: 893–899.

  • Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC and Vogelstein B. . 1989 Nature 342: 705–708.

  • Packham G and Cleveland JL. . 1995 Biochim. Biophys. Acta 1242: 11–28.

  • Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E and Ranzani GN. . 1994 Cancer Res. 54: 1556–1560.

  • Reed JC. . 1995 Curr. Opin. Oncol. 7: 541-–546.

  • Reed JC. . 1997 Nature 387: 773–776.

  • Renault B, van den Broek M, Fodde R, Wijnen J, Pellegata NS, Amadori D, Khan PM and Ranzani GN. . 1993 Cancer Res. 53: 2614–2617.

  • Rupnow BA, Alarcon RM, Giaccia AJ and Knox SJ. . 1998 Cell Death Diff. 5: 141–147.

  • Sakamuro D, Eviner V, Elliott KJ, Showe L, White E and Prendergast GC. . 1995 Oncogene 11: 2411–2418.

  • Sambrook J, Fritsch EF and Maniatis T. . (1989). Cold Spring Harbor Laboratory Press: New York.

  • Shah GM, Poirier D, Duchaine C, Brochu G, Desnoyers S, Lagueux J, Verreault A, Hoflack J-C, Kirkland JB and Poirier GG. . 1995 Anal. Biochem. 227: 1–13.

  • Shaw P, Bovey R, Tardy S, Sahli R, Sordat B and Costa J. . 1992 Proc. Natl. Acad. Sci. USA 89: 4495–4499.

  • Spencer CA and Groudine M. . 1991 Adv. Cancer Res. 56: 1–48.

  • Towbin H, Staehelin T and Gordon J. . 1979 Proc. Natl. Acad. Sci. USA 76: 4350–4354.

  • Vaux DL, Cory S and Adams J. . 1988 Nature 335: 440–442.

  • Wagner AJ, Kokontis JM and Hay N. . 1994 Genes & Dev. 8: 2817–2830.

  • Wagner AJ, Small MB and Hay N. . 1993 Mol. Cell. Biol. 13: 2432–2440.

  • Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A and Oren M. . 1991 Nature 352: 345–347.

Download references

Acknowledgements

We are greatly indebted to Dr G Poirier (Université Laval, Québec, Canada) for the monoclonal antibody C-2-10 and to Prof G Ranzani (IGM, Università di Pavia, Italy) for helpful discussions on p53 experiments. M Donzelli was supported by a fellowship from AIRC (Associazione Italiana per la Ricerca sul Cancro). C Negri and L Padovan are Telethon and Anna Villa Rusconi fellows, respectively. This work was supported in part by grants from the Association pour la Recherche sur le Cancer and from the Ligue Nationale contre le Cancer.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Donzelli, M., Bernardi, R., Negri, C. et al. Apoptosis-prone phenotype of human colon carcinoma cells with a high level amplification of the c-myc gene. Oncogene 18, 439–448 (1999). https://doi.org/10.1038/sj.onc.1202309

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1202309

Keywords

This article is cited by

Search

Quick links